PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

Abstract Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment of prostate cancer are summarized. The advantages and disadvantages of ligands based on monoclonal antibodies and their fragments as well as small molecular PSMA inhibitors are discussed.